KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Account Payables (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Change in Account Payables for 6 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 45.59% year-over-year to $4.4 million, compared with a TTM value of -$2.6 million through Dec 2025, down 140.65%, and an annual FY2025 reading of -$2.6 million, down 140.65% over the prior year.
  • Change in Account Payables was $4.4 million for Q4 2025 at Recursion Pharmaceuticals, up from -$5.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $8.1 million in Q4 2024 and bottomed at -$5.9 million in Q3 2025.
  • Average Change in Account Payables over 5 years is $317200.0, with a median of $383000.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables surged 5790.91% in 2021, then plummeted 1488.73% in 2022.
  • Year by year, Change in Account Payables stood at -$3.5 million in 2021, then skyrocketed by 119.82% to $695000.0 in 2022, then crashed by 145.61% to -$317000.0 in 2023, then soared by 2662.15% to $8.1 million in 2024, then plummeted by 45.59% to $4.4 million in 2025.
  • Business Quant data shows Change in Account Payables for RXRX at $4.4 million in Q4 2025, -$5.9 million in Q3 2025, and -$4.8 million in Q2 2025.